NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

NCT02616666

CompletedPhase 4

Sponsor: University of Liverpool

Conditions: Type 2 Diabetes Mellitus

Interventions: Dapagliflozin, Standard of Care

Countries: United Kingdom

A trial of patients with type 2 diabetes mellitus to evaluate the comparative effectiveness between dapagliflozin and Standard of Care (SOC)

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

For inclusion in the study patients should fulfil the following criteria at the time of screening:

1. Provision of informed consent prior to any study specific procedures
2. Females and males aged ≥18 years up to ≤ 75 years
3. Diagnosed with Type 2 Diabetes Mellitus.
4. Uncontrolled on first-line metformin treatment, defined as ≥8 weeks on maximum tolerated dose of metformin and HbA1c \> 6.5%.
5. Ability to read and write as judged by the investigator.

Exclusion Criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
2. Previous enrolment or randomization in the present study
3. Age \> 75 years
4. Pregnancy/active breast feeding at the time of inclusion
5. Known moderate to severe renal impairment (eGFR\<60ml/min).
6. Participation in an interventional clinical trial ≤ 3 months before enrolment.
7. Unsuitable to participate on mental health grounds, as judged by the investigator.
8. Physician decision to use, as second line treatment, insulin, a GLP1 agonist compound or a SGLT2 inhibitor different from dapagliflozin.
9. Presence of any of the characteristics in which the products in study are contraindicated, as per current labels.
Locations (132)
  • Forfar, Angus, United Kingdom
  • Yate, Avon, United Kingdom
  • Bracknell, Berkshire, United Kingdom
  • Reading, Berkshire, United Kingdom
  • Wokingham, Berkshire, United Kingdom
  • Birmingham, Birmingham, United Kingdom
  • Maesteg, Bridgend, United Kingdom
  • Chew Stoke, Bristol, United Kingdom
  • Yate, Bristol, United Kingdom
  • Iver, Bucks, United Kingdom
  • Blackwood, Caerphilly, United Kingdom
  • Hengoed, Caerphilly, United Kingdom
  • Greenisland, Carrickfergus, United Kingdom
  • Whitehead, Carrickfergus, United Kingdom
  • Macclesfield, Cheshire, United Kingdom
  • Crook, County Durham, United Kingdom
  • Denbigh, Denbighshire, United Kingdom
  • Exeter, Devon, United Kingdom
  • Hull, East Yorkshire, United Kingdom
  • Romford, Essex, United Kingdom
  • Pinhoe, Exeter, United Kingdom
  • Cheltenham, Gloucestershire, United Kingdom
  • Trafford, Greater Manchester, United Kingdom
  • Worsley, Greater Manchester, United Kingdom
  • Alton, Hampshire, United Kingdom
  • Farnborough, Hampshire, United Kingdom
  • Gosport, Hampshire, United Kingdom
  • Havant, Hampshire, United Kingdom
  • Romsey, Hampshire, United Kingdom
  • Southampton, Hampshire, United Kingdom
  • + 102 more on CT.gov